50 岁以上人群新血浆炎症标志物与结直肠肿瘤风险之间的关系。

IF 3.3 3区医学 Q2 ONCOLOGY

Carcinogenesis Pub Date : 2023-12-30 DOI:10.1093/carcin/bgad064

Jia-Yi Su, Yun Wang, Shang-Shang Wu, Wen-Kun Li, Cheng-Yao Wang, Jiu-Yue Ma, Yu-Ting Qiu, Min-Si Zhou, Zhan Wang, Peng Li, Chun-Tao Liu, Jing Wu

{"title":"50 岁以上人群新血浆炎症标志物与结直肠肿瘤风险之间的关系。","authors":"Jia-Yi Su, Yun Wang, Shang-Shang Wu, Wen-Kun Li, Cheng-Yao Wang, Jiu-Yue Ma, Yu-Ting Qiu, Min-Si Zhou, Zhan Wang, Peng Li, Chun-Tao Liu, Jing Wu","doi":"10.1093/carcin/bgad064","DOIUrl":null,"url":null,"abstract":"Objective(s): The prognostic value of systemic cytokine profiles and inflammatory markers in colorectal cancer were explored by several studies. We want to know more about inflammatory biomarkers in colorectal adenoma and early cancer.Method: The level of 38 inflammatory markers in the plasma of 112 adenoma patients, 72 Tis-T1 staging of colorectal carcinoma patients, 34 T2-T4 staging of colorectal carcinoma patients and 53 normal subjects were detected and compared.Result(s): Eight inflammatory biomarkers (Eotaxin, GCSF, IL-4, IL-5, IL-17E, MCP-1, TNF-α and VEGF-A) have higher plasma concentrations in colorectal adenoma and cancer patients compared with normal participants over 50 years old.Conclusion(s): Inflammatory markers may have the prognostic value for colorectal adenoma and early-stage carcinoma.","PeriodicalId":9446,"journal":{"name":"Carcinogenesis","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between new plasma inflammatory markers and risk of colorectal neoplasms in individuals over 50 years old.\",\"authors\":\"Jia-Yi Su, Yun Wang, Shang-Shang Wu, Wen-Kun Li, Cheng-Yao Wang, Jiu-Yue Ma, Yu-Ting Qiu, Min-Si Zhou, Zhan Wang, Peng Li, Chun-Tao Liu, Jing Wu\",\"doi\":\"10.1093/carcin/bgad064\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective(s): The prognostic value of systemic cytokine profiles and inflammatory markers in colorectal cancer were explored by several studies. We want to know more about inflammatory biomarkers in colorectal adenoma and early cancer.Method: The level of 38 inflammatory markers in the plasma of 112 adenoma patients, 72 Tis-T1 staging of colorectal carcinoma patients, 34 T2-T4 staging of colorectal carcinoma patients and 53 normal subjects were detected and compared.Result(s): Eight inflammatory biomarkers (Eotaxin, GCSF, IL-4, IL-5, IL-17E, MCP-1, TNF-α and VEGF-A) have higher plasma concentrations in colorectal adenoma and cancer patients compared with normal participants over 50 years old.Conclusion(s): Inflammatory markers may have the prognostic value for colorectal adenoma and early-stage carcinoma.\",\"PeriodicalId\":9446,\"journal\":{\"name\":\"Carcinogenesis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Carcinogenesis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/carcin/bgad064\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Carcinogenesis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/carcin/bgad064","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

研究目的多项研究探讨了全身细胞因子谱和炎症标志物在结直肠癌中的预后价值。我们希望进一步了解结直肠腺瘤和早期癌症中的炎症生物标志物：方法：检测并比较 112 名腺瘤患者、72 名 Tis-T1 分期大肠癌患者、34 名 T2-T4 分期大肠癌患者和 53 名正常人血浆中 38 种炎症标志物的水平：结果：8种炎症生物标志物（Eotaxin、GCSF、IL-4、IL-5、IL-17E、MCP-1、TNF-α和VEGF-A）在结直肠腺瘤和癌症患者与50岁以上正常人的血浆中浓度较高：炎症标志物可能对结直肠腺瘤和早期癌具有预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association between new plasma inflammatory markers and risk of colorectal neoplasms in individuals over 50 years old.

Objective(s): The prognostic value of systemic cytokine profiles and inflammatory markers in colorectal cancer were explored by several studies. We want to know more about inflammatory biomarkers in colorectal adenoma and early cancer.

Method: The level of 38 inflammatory markers in the plasma of 112 adenoma patients, 72 Tis-T1 staging of colorectal carcinoma patients, 34 T2-T4 staging of colorectal carcinoma patients and 53 normal subjects were detected and compared.

Result(s): Eight inflammatory biomarkers (Eotaxin, GCSF, IL-4, IL-5, IL-17E, MCP-1, TNF-α and VEGF-A) have higher plasma concentrations in colorectal adenoma and cancer patients compared with normal participants over 50 years old.

Conclusion(s): Inflammatory markers may have the prognostic value for colorectal adenoma and early-stage carcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Carcinogenesis 医学-肿瘤学

CiteScore

9.20

自引率

2.10%

发文量

审稿时长

1 months

期刊介绍： Carcinogenesis: Integrative Cancer Research is a multi-disciplinary journal that brings together all the varied aspects of research that will ultimately lead to the prevention of cancer in man. The journal publishes papers that warrant prompt publication in the areas of Biology, Genetics and Epigenetics (including the processes of promotion, progression, signal transduction, apoptosis, genomic instability, growth factors, cell and molecular biology, mutation, DNA repair, genetics, etc.), Cancer Biomarkers and Molecular Epidemiology (including genetic predisposition to cancer, and epidemiology), Inflammation, Microenvironment and Prevention (including molecular dosimetry, chemoprevention, nutrition and cancer, etc.), and Carcinogenesis (including oncogenes and tumor suppressor genes in carcinogenesis, therapy resistance of solid tumors, cancer mouse models, apoptosis and senescence, novel therapeutic targets and cancer drugs).